Clinical Trials Logo

PTEN Gene Inactivation clinical trials

View clinical trials related to PTEN Gene Inactivation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04740190 Recruiting - Clinical trials for Recurrent Glioblastoma

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TAC-GReD
Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib drug penetration through blood-brain barrier. The goal is to estimate the effect size of such combinational treatment approach in recurrent high-grade glioma with DNA damage repair deficiency (dDDR)